Companies · Pharmaceuticals

Vytalyx Inc

AUSTIN · Pharmaceuticals

Diligence memoA one-page analyst read on Vytalyx Inc — recommendation, valuation, rhythm, risks.
$88.4M
Total raised · real
4
Rounds
0.5×
Latest step-up
Top 11%
Sector rank · raised
Series C
Latest stage · inferred · Sun Jul 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Vytalyx Inc looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.91× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era.
  • Within the normal band (91% of peer median) for its niche.
Dormant
  • Last raise 8.0 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Vytalyx Inc is one of 1610 Pharmaceuticals companies tracked from AUSTIN. By capital raised it ranks among the largest (ahead of 90% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(c)
Reg D exemption
2017
Year incorporated
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BPre-Seed · 2017-12-07 Raised $280K (real) Modeled valuation $13M (est)$280K$13MPre-Seed2017Pre-Seed · 2017-12-07 Raised $630K (real) Modeled valuation $30M (est)$630K$30MPre-Seed2017Pre-Seed · 2018-05-01 Raised $300K (real) Modeled valuation $14M (est)$300K$14MPre-Seed2018Pre-Seed · 2018-05-01 Raised $300K (real) Modeled valuation $14M (est)$300K$14MPre-Seed2018Series C · 2018-07-01 Raised $60M (real) Modeled valuation $2.1B (est)$60M$2.1BSeries C2018Series B · 2018-07-01 Raised $28M (real) Modeled valuation $935M (est)$28M$935MSeries B2018+$630K+$300K+$300K+$60M+$28MCumulative $89M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$280K · 2017
Pre-Seed extension$630K · 2017
Pre-Seed extension$300K · 2018
Pre-Seed extension$300K · 2018
Series C$60.0M · 2018no Seed / Series A / Series B on file
Bridge · Series C-stage$27.5M · 2018smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 60%.

Modeled valuation trajectory
$2.1B
Base estimate est.
$194.9M
Conservative case
$5.5B
Upside case
$400.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $13.2M · 2017-12-072017Pre-Seed · modeled $29.8M · 2017-12-07Pre-Seed · modeled $14.2M · 2018-05-01Pre-Seed · modeled $14.2M · 2018-05-01Series C · modeled $2.1B · 2018-07-01Series B · modeled $935.1M · 2018-07-012018
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
66%
Survival probability
49% low · 76% high
1.42×/yr
Annual markup
1.62×/yr upside case
6.0 yr
Elapsed time used
8.0 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
1 mo
Avg between rounds
$156.8M/yr
Capital velocity
8.6 yr
On record since
2017
First round
6
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 11× above median
This company$88.4M
Sector median$8.1M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.6× of median
This company$27.5M
Sector median$46.7M
Modeled value — vs sector median (estimate, all stages) 28× above median
This company$2.1B
Sector median$76.1M

Raised more than 90% of sector peers (real $). Modeled value above 95% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #18 of 32.

This companyCohort peer
$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Amplyx Pharmaceuticals, Inc. · Series C Raised $116.6M · modeled $3.2B (est)Ligand Pharmaceuticals Inc · Series C Raised $85.4M · modeled $3.0B (est)Homology Medicines, Inc. · Series C Raised $127.1M · modeled $2.9B (est)KSQ Therapeutics, Inc. · Series C Raised $80.6M · modeled $2.8B (est)TP Therapeutics, Inc. · Series C Raised $126.4M · modeled $2.8B (est)Milestone Pharmaceuticals Inc. · Series C Raised $91.3M · modeled $2.8B (est)Aprecia Pharmaceuticals Co · Series C Raised $175.4M · modeled $2.8B (est)Tribute Pharmaceuticals Canada Inc. · Series C Raised $92.1M · modeled $2.6B (est)Aralez Pharmaceuticals Inc. · Series C Raised $75.0M · modeled $2.6B (est)Daisy Pharma Opioid Venture, LLC · Series C Raised $75.0M · modeled $2.6B (est)Forty Seven, Inc. · Series C Raised $109.1M · modeled $2.6B (est)MEI Pharma, Inc. · Series C Raised $76.1M · modeled $2.6B (est)Vytalyx Inc (this company) Raised $88.4M · modeled $2.1B (est)Vytalyx Inc
CompanyStageRaised · realValue · estvs peer med.
Amplyx Pharmaceuticals, Inc.Series C$116.6M$3.2B1.38×
Ligand Pharmaceuticals IncSeries C$85.4M$3.0B1.29×
Homology Medicines, Inc.Series C$127.1M$2.9B1.26×
KSQ Therapeutics, Inc.Series C$80.6M$2.8B1.22×
TP Therapeutics, Inc.Series C$126.4M$2.8B1.21×
Milestone Pharmaceuticals Inc.Series C$91.3M$2.8B1.21×
Aprecia Pharmaceuticals CoSeries C$175.4M$2.8B1.19×
Tribute Pharmaceuticals Canada Inc.Series C$92.1M$2.6B1.13×
Aralez Pharmaceuticals Inc.Series C$75.0M$2.6B1.13×
Daisy Pharma Opioid Venture, LLCSeries C$75.0M$2.6B1.13×
Forty Seven, Inc.Series C$109.1M$2.6B1.13×
MEI Pharma, Inc.Series C$76.1M$2.6B1.13×
Vytalyx Inc this companySeries C$88.4M$2.1B0.91×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$280K2017-12-07$1.6M$13.2M90%
Pre-Seed$630K2017-12-07$3.5M$29.8M90%
Pre-Seed$300K2018-05-01$1.7M$14.2M90%
Pre-Seed$300K2018-05-01$1.7M$14.2M90%
Series C$60.0M2018-07-01$400.0M$2.1B90%
Series B$27.5M2018-07-01$152.8M$935.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$280K2017-12-07
    • First recorded raise — entered as Pre-Seed.
    • 5 investors on this round.
  2. Pre-Seed$630K2017-12-07
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.3× larger than the prior — scaling up.
    • 8 investors on this round.
  3. Pre-Seed$300K2018-05-01
    • Came back fast: 5 mo vs the ~13 mo sector norm.
    • Round 2.1× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  4. Pre-Seed$300K2018-05-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  5. Series C$60.0M2018-07-01
    • Came back fast: 2 mo vs the ~13 mo sector norm.
    • Round 200.0× larger than the prior — scaling up.
    • Switched to Rule 506(c) (was Rule 506(b)).
  6. Series B$27.5M2018-07-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.2× smaller than the prior — bridge or down round.
Intelligence
2018 ~Q3
Modeled next raise · ~1mo cadence
$27.5M
Modeled next size est.range $27.5M$44.0M
0.5×
Last step-up
$156.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Alexander Granzotti1 other2017-12
Andre Silvio Granzotti2017-12
Dave Silvio Wentz2018-05
David P Valenti2017-12
David Silvio Valenti2018-05
Gary Silvio Pike2018-05
Jeffrey Silvio Heller2017-12
Jennifer Silvio Tanguy2017-12
John Silvio Hartwig2017-12
Registry & provenance

Vytalyx Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1725469
SEC CIK
2017
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Agios Pharmaceuticals IncPharmaceuticalsSeries C$86.8M$2.7Bsame sector · same stage
Xeris Pharmaceuticals IncPharmaceuticalsSeries C$86.5M$1.1Bsame sector · same stage
Milestone Pharmaceuticals Inc.PharmaceuticalsSeries C$91.3M$2.8Bsame sector · same stage
Ligand Pharmaceuticals IncPharmaceuticalsSeries C$85.4M$3.0Bsame sector · same stage
Sentia Wellness, Inc.PharmaceuticalsSeries C$91.6M$3.2Bsame sector · same stage
Tribute Pharmaceuticals Canada Inc.PharmaceuticalsSeries C$92.1M$2.6Bsame sector · same stage
Paratek Pharmaceuticals IncPharmaceuticalsSeries C$93.0M$3.3Bsame sector · same stage
Mind Medicine (MindMed) Inc.PharmaceuticalsSeries C$83.2M$729.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Vyripharm Enterprises, Inc.PharmaceuticalsSeries D+$7.2B84%
VasoRx, Inc.PharmaceuticalsSeed$117.9M83%
Vapogenix, Inc.PharmaceuticalsSeries A$50.6M83%
Venatorx Pharmaceuticals, Inc.PharmaceuticalsSeries B$420.5M82%
VYNE Therapeutics Inc.PharmaceuticalsSeries C$971.1M82%
Vogenx, Inc.PharmaceuticalsPre-Seed$1.5M82%
Verndari, Inc.PharmaceuticalsSeed$60.3M82%
Vytala, Inc.BiotechnologyPre-Seed$4.7M82%
Frequently asked
How much funding has Vytalyx Inc raised?
Vytalyx Inc has raised approximately $88.4M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Vytalyx Inc's estimated valuation?
Provath's modeled valuation for Vytalyx Inc is approximately $2.1B (modeled range $194.9M–$5.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Vytalyx Inc at?
Vytalyx Inc's latest modeled financing stage is Series C. Its most recent recorded round closed around Sun Jul 01.
What does Vytalyx Inc do and where is it based?
Vytalyx Inc operates in the Pharmaceuticals sector, based in AUSTIN.
Explore related

See where Vytalyx Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Vytalyx Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.